drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor targeting CD19 on B cells to mediate cytotoxic killing.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells, enabling MHC-independent recognition and activation of cytotoxic functions (perforin/granzyme release and cytokine secretion) to eliminate CD19-positive malignant and normal B cells, with in vivo expansion/persistence supporting antitumor activity.
drug_name
Anti-CD19 CAR-T cells
nct_id_drug_ref
NCT05871684